Transcriptomics,Genomics

Dataset Information

37

Exploring chronic drug effects on microengineered human liver cultures using global gene expression profiling


ABSTRACT: Global gene expression profiling is useful for elucidating a drug?s mechanism of action (MOA) on the liver; however, such profiling in rats is not very sensitive for predicting human druginduced liver injury, while de-differentiated monolayers of primary human hepatocytes (PHHs) do not permit chronic drug treatment. In contrast, micropatterned co-cultures (MPCCs) containing PHH colonies and 3T3-J2 fibroblasts maintain a stable liver phenotype for 4-6 weeks. Here, we used MPCCs to test the hypothesis that global gene expression patterns in stable PHHs can be used to distinguish clinical hepatotoxic drugs from their non-liver-toxic analogs and understand the MOA prior to the onset of overt hepatotoxicity. We found that MPCCs treated with the clinical hepatotoxic/non-liver-toxic pair, troglitazone/rosiglitazone, at each drug?s reported and non-toxic Cmax (maximum concentration in human plasma) level for 1, 7, and 14 days displayed a total of 12, 269, and 628 differentially expressed genes, respectively, relative to the vehicle-treated control. Troglitazone modulated >75% of transcripts across pathways such as fatty acid and drug metabolism, oxidative stress, inflammatory response, and complement/coagulation cascades. Escalating rosiglitazone?s dose to that of troglitazone?s Cmax increased modulated transcripts relative to the lower dose; however, over half the identified transcripts were still exclusively modulated by troglitazone. Lastly, other hepatotoxins (nefazodone, ibufenac, and tolcapone) also induced a greater number of differentially expressed genes in MPCCs than their non-liver-toxic analogs (buspirone, ibuprofen, and entacapone) following 7 days of treatment. In conclusion, MPCCs allow evaluation of time- and dose-dependent gene expression patterns in PHHs treated chronically with analog drugs. Overall design: [a] We used Affymetrix microarrays to profile the global gene expression of MPCCs treated with either rosiglitazone or troglitazone relative to DMSO-only controls for 24 hours, 7 days, or 14 days. Global gene expression changes were evaluated as drug-treated conditions against DMSO-only controls. [b] We used Affymetrix microarrays to profile the global gene expression of MPCCs treated with a known hepatotoxin or its non-toxic structural analog relative to a DMSO-only control for 7 days.

INSTRUMENT(S): [HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array

SUBMITTER: Brenton Robert Ware  

PROVIDER: GSE85180 | GEO | 2017-01-01

SECONDARY ACCESSION(S): PRJNA336473

REPOSITORIES: GEO

Similar Datasets

2011-02-11 | E-GEOD-21329 | ArrayExpress
2011-02-11 | GSE21329 | GEO
2007-10-09 | E-GEOD-1458 | ArrayExpress
| PRJNA90011 | ENA
2006-08-11 | E-GEOD-5509 | ArrayExpress
2011-03-18 | E-GEOD-28031 | ArrayExpress
2011-03-18 | GSE28031 | GEO
2015-10-13 | E-GEOD-5509 | ExpressionAtlas
| GSE59565 | GEO
2014-02-14 | E-GEOD-51952 | ArrayExpress